Category: 86393-32-0

On December 4, 2008, Souza, Fabio Eduardo Silva; Oudenes, Jan; Gorin, Boris Ivanovich published a patent.Formula: C17H21ClFN3O4 The title of the patent was Anhydrous ciprofloxacin hydrochloride. And the patent contained the following:

The present invention provides a new anhydrous crystalline form of ciprofloxacin-HCl that is substantially free from solvent mols., and processes of preparation thereof. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Formula: C17H21ClFN3O4

The Article related to ciprofloxacin hydrochloride anhydrous, Pharmaceuticals: Pharmaceutics and other aspects.Formula: C17H21ClFN3O4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On December 31, 2007, Raina, R.; Prawez, S.; Dimitrova, D. J.; Verma, P. K.; Pankaj, N. K. published an article.Product Details of 86393-32-0 The title of the article was Pharmacokinetics of ciprofloxacin following intravenous administration in WLH chickens (Gallus domesticus). And the article contained the following:

Pharmacokinetics of ciprofloxacin was studied in WLH chicken after single i.v. dose @ 4 mg.kg-1 body weight Plasma ciprofloxacin concentrations were analyzed by microbiol. assay technique using E. coli ATCC-25922 as test organisms grown. The determination of the best-fit compartment model and initial estimates of the model-dependent pharmacokinetics was analyzed for each bird by Top-Fit v. 2.0 computer program. The three compartment open model was the best fit for i.v. injection of ciprofloxacin. Statistical moments were also used to compute the noncompartmental pharmacokinetic anal. The elimination half life (t1/2β), volume of distribution from central compartment (Vc) and total body clearance (ClB) were 5.79±1.14 h, 0.85±0.07 L.kg-1 and 16.27±1.87mL.min-1.kg-1, resp. The mean residence time (MRT) and area under the plasma concentration vs time curve from 0 to ∞ (AUC0→ ∞) were 7.05±1.34 h and 4.54±0.59 μg.h.ml-1, resp. The variation coefficient of the technique for the intraassay and interassay precission was less than 10% in the range of standard concentration The lower limit of sensitivity of the ciprofloxacin assay was 0.015 μg.ml-1. The serum concentration at time zero (Cp°) and area under the curve from 0 to 24h (AUC0-24) were applied in the calculation of predictors of efficacy for concentration-dependent antibiotics. Ciprofloxacin concentration in plasma of chickens, maintaining min. inhibitory concentration (MIC <1 μg.ml-1) for upto 12 h after i.v. administration @ 4mg.kg-1, would be adequate for controlling avian bacterial diseases. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Product Details of 86393-32-0

The Article related to antimicrobial pharmacokinetics pharmacodynamics ciprofloxacin hydrochloride monohydrate escherichia pasteurella gallus, Pharmacology: Drug Metabolism and other aspects.Product Details of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On March 31, 1996, Rispal, Patric; Grellet, Jean; Celerier, Christophe; Breilh, Dominique; Dorian, Martine; Pellegrin, Jean Luc; Saux, Marie Claude; Leng, Bernard published an article.Safety of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate The title of the article was Comparative uptake of sparfloxacin and ciprofloxacin into human THP 1 monocytic cells: evidence for an organic anion transport. And the article contained the following:

The uptake of sparfloxacin (CAS 11542-93-9) by human monocytes was studied by comparison with ciprofloxacin (CAS 86393-32-0). The human monocytic THP 1 cells were incubated with the antibiotics for 2 h. Entry of antimicrobials into the cells was determined by means of a velocity gradient centrifugation technique and HPLC assay. Antibiotic uptake was expressed as the ratio of the intracellular to the extracellular drug concentration (IC/EC). Quinolones enter readily in monocytic cells but sparfloxacin is taken up more rapidly than ciprofloxacin. At steady-state the IC/EC ratio of sparfloxacin (9.07) is higher than IC-EC of ciprofloxacin (4.29). Characterization of quinolone uptake suggests that these drugs penetrate throughout the THP 1 membrane by passive diffusion. However, the results of the present study indicate that addnl. mechanisms may contribute to intracellular accumulation of ciprofloxacin and sparfloxacin but does not modify IC/EC of sparfloxacin. It can be concluded that human monocyte-like cells have functional organic anion transporters and that this way of secretion is quinolone selective. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Safety of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

The Article related to sparfloxacin ciprofloxacin monocyte organic anion transport, Pharmacology: Drug Metabolism and other aspects.Safety of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On May 15, 2020, Kim, Jeong Hyeon; Han, Hyo Won; Han, Hyeong Jun published a patent.Category: piperazines The title of the patent was Infectious disease-treating drug screening method based on pluripotent stem cell-derived macrophages. And the patent contained the following:

The infectious disease-treating or preventing drug screening method uses pluripotent stem cell-derived macrophages (eMAC) with more similar gene expression with macrophages (hMDM) in human blood as compared with existing mouse-derived cell line (Raw264.7) and human-derived macrophage cell line (ThP-1) used for screening tuberculostatic drug. The screening method has an excellent screening effect when compared with the conventional screening methods. A tuberculostatic drug screening method that can be useful for new drug development and quality control of existing tuberculostatic drugs is provided. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Category: piperazines

The Article related to infectious disease drug screening pluripotent stem cell macrophage, Placeholder for records without volume info and other aspects.Category: piperazines

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On May 15, 2020, Kim, Jeong Hyeon; Han, Hyo Won; Han, Hyeong Jun published a patent.Category: piperazines The title of the patent was Infectious disease-treating drug screening method based on pluripotent stem cell-derived macrophages. And the patent contained the following:

The infectious disease-treating or preventing drug screening method uses pluripotent stem cell-derived macrophages (eMAC) with more similar gene expression with macrophages (hMDM) in human blood as compared with existing mouse-derived cell line (Raw264.7) and human-derived macrophage cell line (ThP-1) used for screening tuberculostatic drug. The screening method has an excellent screening effect when compared with the conventional screening methods. A tuberculostatic drug screening method that can be useful for new drug development and quality control of existing tuberculostatic drugs is provided. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Category: piperazines

The Article related to infectious disease drug screening pluripotent stem cell macrophage, Placeholder for records without volume info and other aspects.Category: piperazines

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Tao, Yun-Feng; He, Yu-Juan; Ye, Jin-Zhi; Yang, Xiao; Yang, Ying-Ying; Xie, Ge-Ge; Liu, Lan-Xiang; Du, Guan-Ben; Zhang, Hong; Zhou, Bei published an article in 2021, the title of the article was Cochineal quinone carbon dot synthesis via a keto-enol tautomerism strategy and their intermolecular photo-induced cross-redox interactions with tetracycline.Safety of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate And the article contains the following content:

Natural product-originated carbon dots represent a charming and valuable platform for bio-fluorescence probes; however, the application scope of these probes is seriously restricted, due to the indistinct mol. structures of these bio-probes and the inaccurate interactions between the probe and detected guest mol. Herein, a novel strategy of keto-enol tautomerism-mediated quinone aromatization was achieved for Cochineal bio-based quinone carbon dot synthesis. Then, a photo-induced intermol. cross-redox reaction was accomplished with tetracycline for quinone carbon dot mol. transformation and fluorescence change. This work represents a pioneer for intermol. interaction simulation and bonding energy evaluation of carbon dots for trace organics detection. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Safety of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

The Article related to cochineal quinone carbon dot keto enol tautomerism, intermol photoinduced cross redox interaction tetracycline, Organic Analytical Chemistry: Apparatus and other aspects.Safety of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On January 31, 2012, Hou, Jian-bo; Xie, Wen; Chen, Xiao-mei; Qian, Yan; Xi, Jun-yang; Wang, Feng; He, Jian-min; Liu, Hai-shan published an article.Application of 86393-32-0 The title of the article was Simultaneous determination of 54 drugs residues in pork by high performance liquid chromatography-tandem mass spectrometry and isotopes dilution technique. And the article contained the following:

A simultaneous method for the determination of 54 drugs residues (sulfonamides, nitroimidazoles, quinolones, macrolide antibiotics, lincosamides and praziquantel) in pork was developed and validated by high performance liquid chromatog.-tandem mass spectrometry (HPLC-MS/MS) following solid phase extraction (SPE). The extracts were dissolved and distilled with acetonitrile. After that the supernatant solution was extracted with n-hexane to remove the fat, and then cleaned up with SPE C18 cartridges. The quant. detection was performed on LC-MS/MS by multiple reaction monitoring (MRM) mode under pos. electrospray ionization (ESI+). The one precursor/two product ion transitions were used for each compound Isotopes dilution internal standard method was used to determine the residue contents in pork. The limits of quantification (LOQs) are 1.0 μg/kg (sulfonamides and nitroimidazoles), 2.0 μg/kg (quinolones and lincosamides), 3.0 μg/kg (macrolide antibiotics) and 0.3 μg/kg (praziquantel), resp. Validation parameters are determined as follow correlation coefficients, which are more than 0.991, and the recovery for each analyte ranges of 20.9%-121% with relative standard deviations (RSDs) between 2.0% and 19.8%. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Application of 86393-32-0

The Article related to pork drug residue hplc isotope dilution mass spectrometry, Food and Feed Chemistry: Analysis and other aspects.Application of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On March 1, 2010, Sander, Kerstin; von Coburg, Yvonne; Camelin, Jean-Claude; Ligneau, Xavier; Rau, Oliver; Schubert-Zsilavecz, Manfred; Schwartz, Jean-Charles; Stark, Holger published an article.Application of 86393-32-0 The title of the article was Acidic elements in histamine H3 receptor antagonists. And the article contained the following:

Antagonists of the human histamine H3 receptor (hH3R) often contain a second basic moiety, which is well known to boost affinity on this histamine receptor subtype. Here, we prepared compounds with acidic moieties of different pK a values to figure out that the hH3R tolerates these functionalities when added to a common pharmacophore blueprint. Depending on the acidic, electronic and steric features the designed ligands showed hH3R affinities in the nanomolar concentration range. Addnl., selected ligands were tested but failed as dual acting hH3R/hPPAR (human peroxisome proliferator-activated receptor) ligands. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Application of 86393-32-0

The Article related to h3 antagonist acidic moiety preparation structure activity crystal structure, antihistamine h3 antagonist acidic moiety preparation structure activity, Pharmacology: Structure-Activity and other aspects.Application of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On July 17, 2001, Lee, Fang-yu published a patent.Quality Control of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate The title of the patent was Oral antimicrobial formulations of ciprofloxacin. And the patent contained the following:

The invention provides 3 oral ciprofloxacin formulations, with the first formulation comprising 60-75% ciprofloxacin or its salt, 0.3-10% pregelatinized starch as binder, 5-30% lactose as diluent, 1-10% of sodium starch glycolate as disintegrant and 0.5-2% magnesium stearate as lubricant. The second formulation comprises 60-75% ciprofloxacin or its salt, 1-5% polyvinylpyrrolidone as binder, 5-30% lactose as diluent; 1-10% sodium starch glycolate as disintegrant, and 0.5-2% magnesium stearate as lubricant. The third formulation comprises 60-75% ciprofloxacin or salt, 1-8% poly(vinyl alc.) as binder, 5-30% lactose as diluent, 1-10% sodium starch glycolate as disintegrant, and 0.5-2% magnesium stearate as lubricant. The ciprofloxacin, the binder, the diluent, the disintegrant, and the lubricant are first mixed in a dry state to form a powder mixture, followed by mixing with a water-solvent solution to convert the dry powder mixture into a wet powder mixture before grinding and granulating the wet powder mixture into wet granules, which are further dried to form dry granules. The above 3 formulations do not contain cellulose. Thus, tablets contained ciprofloxacin 70, PVP-K30 2, sodium starch glycolate 5, lactose 21, and Mg stearate 2%. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Quality Control of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

The Article related to antimicrobial ciprofloxacin oral, Pharmaceuticals: Formulation and Compounding and other aspects.Quality Control of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On March 31, 2000, Tsvetkov, Plamen K.; Velikova, Evtimija I; Kafedzhiiski, Stefan K.; Stoyanov, Simeon I; Dimitrova, Silvija S.; Evstatieva, Anka V; Stoyanova, Evgenija K. published a patent.SDS of cas: 86393-32-0 The title of the patent was Composition and method for the preparation of a medicament dosage form. And the patent contained the following:

The invention relates to a composition and method for the preparation of a medicament form based on 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-1-(1-piperazinyl)-quinolin-3-carboxylic acid monohydrochloride, known as ciprofloxacin, which is applied as antibacterial medicine in the medical practice. The composition includes: ciprofloxacin hydrochloride monohydrate and lactose monohydrate in ratio 4.93:1, mannitol SD 200, microcrystalline cellulose, sodium starch glycolate, colloid silicon dioxide, talcum and magnesium stearate. The medicamentous form is produced when ciprofloxacin and lactose monohydrate are mixed in a mixer granulator and are homogenized at speeds: 98 r.p.m. for the small blade, and 1500 r.p.m. for the large blade. Sep., the dissolved sodium starch glycolate is added at continuous agitation to the homogenized mixture Granular mass is produced which is dried at 45-50°C to residual moisture of 3% and is calibrated. To the dry granular mass mannitol SD 200, microcrystalline cellulose, sodium starch glycolate, colloid silicon dioxide, talcum and magnesium stearate. The medicamentous form is produced when ciprofloxacin and lactose monohydrate are mixed in a mixer granulator and are homogenized at speeds: 98 r.p.m. for the small blade, and 1500 r.p.m. for the large blade. Sep., the dissolved sodium starch glycolate is added at continuous agitation to the homogenized mixture Granular mass is produced which is dried at 45-50°C to residual moisture of 3% and is calibrated. To the dry granular mass mannitol SD 200, microcrystalline cellulose, colloidal silicon dioxide, talcum and magnesium stearate are added. The mixture produced is homogenized. A water impermeable layer of a film with Opadry is applied. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).SDS of cas: 86393-32-0

The Article related to ciprofloxacin dosage film tablet, Pharmaceuticals: Formulation and Compounding and other aspects.SDS of cas: 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics